Vinorelbine tartrate

Comprehensive Product Overview

In modern chemotherapy, Vinorelbine Tartrate is recognized for its targeted interference with cell division. Its primary mechanism involves binding to tubulin, the protein subunit of microtubules. First, this binding prevents the polymerization of tubulin into microtubules during the mitotic phase (M-phase) of the cell cycle. As a result, the mitotic spindle cannot form correctly, leading to cell cycle arrest and subsequent apoptosis of malignant cells. Zyntex provides Vinorelbine Tartrate with a high degree of crystalline purity, ensuring predictable pharmacokinetics for both intravenous infusion and soft-gel capsule applications.

Zyntex ensures that our Vinorelbine Tartrate meets stringent global standards for related substances and residual solvents. Because of its high cytotoxic potency, we prioritize absolute batch-to-batch consistency to support oncology clinics in maintaining precise dosing regimens. It is predominantly used as a first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC) and as a secondary treatment for metastatic breast cancer, often in combination with cisplatin or other chemotherapeutic agents. Moreover, its modified structure allows for a lower incidence of neurotoxicity compared to vincristine. Consequently, our product enables pharmaceutical manufacturers to produce highly effective, specialized cancer treatments that balance efficacy with patient tolerability. Finally, our dedicated regulatory team provides the necessary DMF (Drug Master File) documentation to support your international registration and compliance needs.

Key Oncological Applications

This potent antineoplastic API is a cornerstone in several critical cancer treatment protocols:

Technical Specifications